help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McKenna, N. J.
Right arrow Articles by O’Malley, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McKenna, N. J.
Right arrow Articles by O’Malley, B. W.
Endocrinology Vol. 143, No. 7 2461-2465
Copyright © 2002 by The Endocrine Society


RECEPTORS

Minireview: Nuclear Receptor Coactivators—An Update

Neil J. McKenna and Bert W. O’Malley

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030

Address all correspondence and requests for reprints to: Bert W. O’Malley, M.D., Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030. E-mail: . berto{at}bcm.tmc.edu


    Abstract
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
Nuclear receptors (NRs) regulate the expression of target genes in response to activation by steroid hormones and other ligands, as well as a variety of other signaling pathways. NR coactivators are defined as cellular factors recruited by activated NRs that complement their function as mediators of the cellular response to endocrine signals. In this review, we will focus upon advances in our understanding of the function of coactivators as their characterization has progressed from mechanistic studies to an exploration of their biological roles in living animals.


    Introduction
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
NUCLEAR RECEPTORS (NRs) are transcription factors that regulate the expression of target genes in response to steroid hormones and other ligands. The biological effects of these ligands are manifest in processes ranging from organogenesis during development, to regulation of metabolic pathways, to stimulating proliferation in reproductive tissues. Approximately 50 NRs are known to exist, and together, these proteins comprise one of the largest families of metazoan transcription factors, the NR superfamily, whose structure is defined by a number of signature functional domains (1, 2, 3). Generally, NRs are comprised of: an amino-terminal activation function, activation function (AF)-1 (A/B domain); the DNA-binding domain; a hinge region; and a carboxy-terminal ligand-binding domain containing a second activation function, AF-2.

NR coregulators can be broadly defined as cellular factors recruited by NRs that complement their function as mediators of the cellular response to endocrine signals. They are generally divisible into coregulators that promote transcriptional activation when recruited (coactivators), and those that attenuate promoter activity (corepressors). A discussion of the role of corepressors in NR function is beyond the scope of this minireview, and the reader is referred to recent reviews for thorough coverage of this topic (4, 5). We will highlight advances in our understanding of the function of coactivators as their characterization has progressed from in vitro studies to an evaluation of their biological significance in living animals.

A large number of coactivators are known to exist, and over recent years, their study has been firmly established as a research field in its own right. While progress has been made toward elucidating their functions at promoters, the issues of the physiological and metabolic roles of coactivators, their tissue distribution, and their contribution to functional diversity of NR action in vivo, remain largely unresolved. A recurring question in the field is the molecular basis for the number of individual coactivators, and the extent to which receptors and coactivators effect differential spatiotemporal responses to ligands at the organism, tissue and gene levels.


    In Vitro Characterization of Coactivators: A Molecular Model
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
Progress to date in characterizing the function of coactivators on a mechanistic level has constructed a composite model of their role in NR action (Fig. 1Go). Initial contact between activated NRs and coactivators is believed to be mediated in large part by an amphipathic helix conserved on the surface of most coactivators, the LXXLL motif, or NR box (6). Crystallographic evidence has shown that a ligand-dependent shift in the position of several critical helices in AF-2 of the receptor ligand binding domain, notably helix 12, creates a thermodynamically secure environment for the coactivator NR box (7). This relatively localized union between receptor and coregulator suggests that it may hold considerable potential for peptide-based therapeutic manipulation of NR pharmacology, and as a flexible, informative basis for ligand screening assays (8).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 1. General model of coactivator function in transcriptional regulation by nuclear receptors. See text for details. Hi, Histones. Due to space and reference limitations we are unable to cite references for individual coactivators, and instead refer the reader to more in-depth recent reviews (4 5 ).

 

    Chromatin—Remodeling Factors
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
One of the primary functions of activated receptors can be viewed essentially as facilitating access of the basal transcription machinery to the promoter to initiate transcription. Chromatin plays an important role in regulating the basal activity of many promoters, and molecules designed to overcome the thermodynamic constraints it imposes are thought to be recruited at an early point in the model of receptor action (Fig. 1Go). Perhaps the best characterized of these is the adenosine 5'-triphosphatase (ATPase)-containing multiprotein SWI/SNF complex containing proteins initially identified in yeast. ATPase-defective mutants of this complex can uncouple the transcriptional function of certain NRs in cell culture (9). Other proteins implicated in chromatin remodeling are the Su(var)3-9/enhancer of zeste/trithorax (SET) domain-containing factor NR-binding SET domain-containing protein and transcription intermediary factor-{alpha} (TIF1{alpha}).


    Acetyltransferases
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
While ATPase complexes are thought to largely effect noncovalent disruption of large chromatin domains, local regulation of histone-histone and histone-DNA interactions are mediated in part by members of a family of proteins that were among the first to be identified as NR coactivators, the steroid receptor coactivator (SRC)/p160 family. Members of the SRC family [SRC-1/nuclear coactivator-1 (10, 11); glucocorticoid receptor-interacting protein-1/TIF2/SRC-2 (12, 13); and p300/cAMP response element binding protein (CREB)-binding protein-interacting protein/activator of thyroid receptor/amplified in breast cancer-1/receptor-associated coactivator-3/thyroid receptor-associated molecule-1/SRC-3 (14, 15, 16, 17, 18, 19)] contain a number of shared domains, including a central region containing repeating NR boxes.

The structural homology between SRC family members is reflected in their overlapping functional properties, such as acetyltransferase activity. Histones are thought to maintain a repressive transcriptional environment at the promoter through electrostatic contacts between positively charged lysine side chains and negatively charged DNA phosphate groups. By catalyzing the acetylation of histone lysines, SRC family members and other histone acetyltransferases such as CREB-binding protein (CBP) and p300 (see below) are thought to disrupt the interactions responsible for maintaining the promoter region in a "closed" state. Of the SRC family members, SRC-1 and ACTR/SRC-3 have been shown to possess intrinsic acetyltransferase activity (15, 20)

The physiological role of SRC/p160s as coactivators has been implied by knockout studies of genes encoding these proteins (21, 22, 23). Although the phenotypes of these knockouts are largely subtle in nature, they do provide some clues as to their functions, and to significant differences between SRC/p160 family members. SRC-1 knockout mice show a partial resistance to hormones and a reduced growth and development of various steroid target organs. SRC-3 knockout mice show reduced growth and female reproduction, and lack of mammary gland development. In addition, mouse embryonic fibroblasts or liver cells derived from these SRC-3-/- mice are insensitive to growth stimulation by IGF-1 or GH. The participation of SRC-3 in cell growth is further supported by its role in various cancers—it has been demonstrated that the SRC-3 gene is amplified in 5–10% of breast tumors and 7–8% of ovarian cancer samples (19).

Along with the SRC family, another well characterized NR coactivator is CBP and its closely related factor, p300, which have been shown to complement the activities of many transcription factors, including p53 and NRs (24, 25). Like the SRC/p160 family members SRC-1 and ACTR/SRC-3. CBP and p300 contain intrinsic acetyltransferase activity and appear to be the predominant acetyltransferases for histones. Unlike SRC/p160 family members, however, heterozygous and null mutants of CBP and p300 exhibit dosage-dependent pleiotropic defects in a variety of morphogenetic and cell differentiation processes, indicating their importance in early mammalian development (26, 27). This apparent partitioning of coactivator function in different developmental stages is one possible clue to the profusion of coactivators that exists to mediate NR function.


    Contact with General Transcription Factors
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
A third prominent group of coactivators is represented by thyroid receptor-associated proteins (TRAP)/vitamin D receptor-interacting proteins (DRIP), a complex initially identified in separate biochemical screens for proteins recruited by thyroid hormone receptor (28) and vitamin D receptor (29), respectively. Subsequent studies have shown TRAP/DRIP to be capable of enhancing the function of other receptor types, and this has been interpreted as evidence of a general role of the complex in NR-mediated signaling. Molecular studies indicate that the complex may play a role in directly contacting the basal transcriptional machinery. Consistent with such a pivotal role in NR-mediated transcriptional regulation, null mutation of the gene encoding a NR box-containing TRAP/DRIP subunit (TRAP220) results in embryonic lethality attributable to a variety of pleiotropic abnormalities (30), including defects in cell cycle regulation and increased apoptosis.


    Regulating Coactivators: Posttranslational Modification
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
How are the functional properties of a given number of coactivators partitioned to account for their ability to integrate NR function at a wide variety of promoters with a broad spectrum of cellular signals? To pose the question another way, how might coactivators be addressed to mediate the specific spatiotemporal fingerprint for given genes or gene sets? One school of thought suggests that posttranslational modifications such as acetylation or phosphorylation may have a role in specifying the codes that tune a given coactivator to a specific mechanistic role. One of the first studies to highlight their potent influence upon the molecular choreography of NRs and their coregulators at specific promoters was the demonstration of p300-mediated acetylation of lysine residues in the vicinity of the ACTR/SRC-3 NR boxes that resulted in the uncoupling of the interaction between the estrogen receptor (ER) and ACTR on pS2, cathepsin D, and c-myc promoters (31). More recently, chromatin immunoprecipitation analysis of the p21 promoter has shown that mutation of the p53 target acetylation region prevented its recruitment of coactivator complexes, including CBP (32). These studies are reminiscent of earlier studies describing promoter-specific functions of individual coactivators, and highlight the importance of promoter and transcription factor context in determining the functional consequences of posttranslational modification.

Phosphorylation, which has been historically implicated in NR function (33), is currently emerging as a critical posttranslational modification in the context of coactivators, and its effect takes a variety of forms. Knutti et al. (34) have shown that p38 MAPK-mediated phosphorylation of peroxisomal proliferator-activated receptor-{gamma}-coactivator-1 results in reversal of its sequestration in a nonfunctional complex by a repressor. In a further example of the context dependency of posttranslational modification, phosphorylation of amplified in breast cancer-1/SRC-3 by MAPK increases the half life of its association with p300 (35). Moreover, phosphorylation has been shown to enhance acetyltransferase activity, and can function as a determinant of the subcellular localization of coactivators (for a review, see Refs. 4 and 5). These studies and others present a molecular basis for the well-characterized functional cross talk between NRs and growth factors to which many endocrinological studies have pointed. Taken together, they suggest that to us that transcription factor-specific, coactivator-specific, and promoter-customized sequences of posttranslational modification may contribute to the amplitude, timing and duration of transcription of individual genes.

To summarize, in vitro molecular approaches have constructed a sequential model of coactivator action that envisages recruitment by receptor of chromatin modifying factors, followed by histone and factor acetyltransferase activity, with TRAP/DRIP-like complexes ultimately contacting basal transcription factors (Fig. 1Go). Recent studies have hinted at a role for coactivators in influencing events downstream of transcriptional initiation (36, 37), although the precise nature of these roles is as yet unclear. Orchestrating the recruitment and participation of individual factors in this sequence of events is a series of posttranslational modifications, which might occur in a promoter-specific context. Given this basic model, scenarios can be envisaged that might require adaptation of this basic framework. For example, the model assumes the existence of a restrictive chromatin milieu requiring recruitment of an initial battery of chromatin-modifying coregulators to facilitate access of secondary TRAP/DRIP-like coregulator complexes to the promoter. What series of events might account for NR regulation of a promoter that is already active in response to signaling by another, distinct signaling axis? Intuitively, a permissive chromatin environment might be less likely to require the incorporation of chromatin modifying complexes or histone acetyltransferases activities by the receptor.


    Receptor and Ligand-Specific Coactivator Recruitment
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
The selective recruitment of coactivators by individual receptors has been well established (38, 39). Moreover, the intricate spatiotemporal pharmacology of NR ligands and their synthetic derivatives, the selective receptor modulators, may be attributable in part to their ability to specify the identity of coactivators recruited by individual receptors. Vitamin D receptor, for example, has been reported to discriminate between SRC-1 and TIF2/SRC-2 to different degrees depending upon the ligand to which it is bound (40). Moreover, distinct ER{alpha} and ERß ligands are known to effect preferential recruitment of different coactivators (41, 42). The attribution of such effects to ligand-specific manipulation of receptor tertiary structure is supported by crystallographic studies of ER bound to different selective ER modulators; see Ref. 7). Moreover, in the case of peroxisomal proliferator-activated receptor-{gamma}, the synthetic antidiabetic roziglitazone effects selective recruitment of TIF2, whereas a leucine-containing peptide induces an allosterically unique conformation, and is associated with a distinct peroxisomal proliferator-activated receptor pharmacology and target gene induction specificity (43). Selective receptor/coactivator interactions represent an efficient system through which the pleiotropic effects of NR ligands might be mediated, and are likely further determined by tissue-specific patterns of posttranslational modification of coactivators (44).


    What Are the Biological Roles of Coactivators?
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
There is a limit to the complexity of coactivator function that the essentially composite model of NR and coactivator action we have discussed (Fig. 1Go) is capable of conveying. As alluded to above, emerging evidence suggests that coactivator function is a highly contextual chain of events, pointing to what is likely a rich and complex biology for these factors. While null deletions have indicated that several coactivators (CBP, p300, TRAP/DRIP) are essential for viability, these are likely to be the exception, and the majority of these factors will likely require more subtle approaches to defining their biological roles. While we have cited promoter context as an important variable, a variety of studies have highlighted receptor and ligand identity and tissue specificity as other principal determinants of coactivator function.

Recent in vivo studies have highlighted important distinctions between individual groups of coactivators for which their initial molecular characterization did not initially account. Evidence is emerging that specific coactivator fingerprints may determine the spatiotemporal response of individual tissues to distinct hormones. For example, the androgen receptor, ER, and progesterone receptor coactivator E6-associated protein (AP) is expressed in both the virgin mammary gland and the prostate. Studies of the E6-AP null mutant indicate, however, that it is redundant for estrogen and progesterone-induced mammary gland growth while required for proper testosterone-mediated prostate gland growth (45). These results stand in contrast to the impaired mammary gland development characteristic of the SRC-1 and SRC-3 null mutants. In turn, in contrast to the tissue-specific phenotypes of E6-AP and SRC-1/3 null mutant animals, the severe developmental phenotypes resulting from deletion of PBP/TRAP220, CBP, and p300 are consistent with their evolutionary conservation, and their mediation of a very broad range of cellular signals. Their in vivo characterization suggests they may play a role in integrating multiple cellular stimuli at critical transcriptional loci during fundamental developmental processes.


    Considerations for the Future
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 
Initial mechanistic approaches that invested coactivators with an amplificatory role at NR-regulated promoters were predicated upon an enhancement of NR function in transient transfection and, more recently, in in vitro transcription assays. These observations were made in the context of cultured cells containing supraphysiological levels of coactivator, receptor and synthetic template. Such assays, which vary with respect to cell type, DNA amounts, vector and reporter type, and promoter activity assay method, do not readily lend themselves to comparative quantitative analysis. While they and other assays have been of great value in the functional characterization of coactivators, they afford only the most tenuous biological extrapolation. There is little reason to suppose that native promoters in vivo would support the levels of amplification observed in transient transfection. Indeed, in vivo demonstrations of ligand response in wild-type and coactivator null mutant mice point to a role for coactivators in a rather more complex regulatory scenario.

One of the principal issues confronting the field is the need to reconcile the wealth of in vitro observations with a complete in vivo picture of coactivator biology. A firmer grounding in the cellular physiology of coactivators should greatly aid investigators seeking to explore the pathological ramifications of coactivator mis-expression or mutation. The strides taken toward characterizing the mechanistic complexities of many coactivators gives hope for the future, and we anticipate many intriguing twists as the biology of coactivators unfolds in the near future.


    Acknowledgments
 
We thank Drs. Austin Cooney, Fred Pereira, and Zafar Nawaz for helpful comments.


    Footnotes
 
Work leading to the conclusions summarized herein was supported by the National Institute of Child Health and Human Development and the National Institute of Diabetes, Digestive and Kidney Diseases. N.J.McK. is a recipient of a Department of Defense Breast Cancer Postdoctoral Research Fellowship.

Abbreviations: AF, Activation function; ATPase, adenosine 5'-triphosphatase; CBP, CREB binding protein; CREB, cAMP response element binding protein; DRIP, vitamin D receptor-interacting proteins; E6-AP, E6-associated protein; ER, estrogen receptor; NR, nuclear receptor; SET, Su(var)3-9/enhancer of zeste/trithorax; SRC, steroid receptor coactivator; TIF1{alpha}, transcription intermediary factor-{alpha}; TRAP, thyroid receptor-associated proteins.

Received December 13, 2001.

Accepted for publication March 13, 2002.


    References
 Top
 Abstract
 Introduction
 In Vitro Characterization of...
 Chromatin—Remodeling...
 Acetyltransferases
 Contact with General...
 Regulating Coactivators:...
 Receptor and Ligand-Specific...
 What Are the Biological...
 Considerations for the Future
 References
 

  1. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889–895[Abstract/Free Full Text]
  2. Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841–850[CrossRef][Medline]
  3. Tsai MJ, O’Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451–486[CrossRef][Medline]
  4. Rosenfeld MG, Glass CK 2001 Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:36865–36868[Free Full Text]
  5. McKenna NJ, O’Malley BW 2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465–474[CrossRef][Medline]
  6. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736[CrossRef][Medline]
  7. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927–937[CrossRef][Medline]
  8. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP 1999 Peptide antagonists of the human estrogen receptor. Science 285:744–746[Abstract/Free Full Text]
  9. Wade PA, Wolffe AP 1999 Transcriptional regulation: SWItching circuitry. Curr Biol 9:R221–R224
  10. Onate SA, Tsai SY, Tsai MJ, O’Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354–1357[Abstract/Free Full Text]
  11. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403–414[CrossRef][Medline]
  12. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948–4952[Abstract/Free Full Text]
  13. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667–3675[Medline]
  14. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677–684[CrossRef][Medline]
  15. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580[CrossRef][Medline]
  16. Li H, Gomes PJ, Chen JD 1997 RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94:8479–8484[Abstract/Free Full Text]
  17. Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE 1998 A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 273:27645–653[Abstract/Free Full Text]
  18. Takeshita A, Cardona GR, Koibuchi N, Suen C-S, Chin WW 1997 TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 272:27629–27634[Abstract/Free Full Text]
  19. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968[Abstract/Free Full Text]
  20. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou JX, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai M-J, O’Malley BW 1997 Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194–198[CrossRef][Medline]
  21. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O’Malley BW 1998 Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922–1925[Abstract/Free Full Text]
  22. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O’Malley BW 2000 The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97:6379–6384[Abstract/Free Full Text]
  23. Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG 2000 Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA 97:13549–13554[Abstract/Free Full Text]
  24. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM 1996 Role of CBP/p300 in nuclear receptor signalling. Nature 383:99–103[CrossRef][Medline]
  25. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM 1997 Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823–827[CrossRef][Medline]
  26. Kung AL, Rebel VI, Bronson RT, Ch’ng LE, Sieff CA, Livingston DM, Yao TP 2000 Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 14:272–277[Abstract/Free Full Text]
  27. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch’ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R 1998 Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361–372[CrossRef][Medline]
  28. Fondell JD, Ge H, Roeder RG 1996 Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA 93:8329–8333[Abstract/Free Full Text]
  29. Rachez C, Suldan Z, Ward J, Chang CP, Burakov D, Erdjument-Bromage H, Tempst P, Freedman LP 1998 A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12:1787–1800[Abstract/Free Full Text]
  30. Ito M, Yuan CX, Okano HJ, Darnell RB, Roeder RG 2000 Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Mol Cell 5:683–693[CrossRef][Medline]
  31. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675–686[CrossRef][Medline]
  32. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL 2001 Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8:1243–1254[CrossRef][Medline]
  33. Weigel NL 1996 Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657–667
  34. Knutti D, Kressler D, Kralli A 2001 Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci USA 98:9713–9718[Abstract/Free Full Text]
  35. Font de Mora J, Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041–5047[Abstract/Free Full Text]
  36. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM 2000 Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 6:307–316[CrossRef][Medline]
  37. Hoenig A, Auboeuf D, O’Malley BW, Berget S, Regulation of alternative splicing by the ATp-dependent DEAD box RNA helicase p72. Mol Cell Biol, in press
  38. Warnmark A, Almlof T, Leers J, Gustafsson JA, Treuter E 2001 Differential recruitment of the mammalian mediator subunit TRAP220 by estrogen receptors ER{alpha} and ERß. J Biol Chem 276:23397–23404[Abstract/Free Full Text]
  39. Wong CW, Komm B, Cheskis BJ 2001 Structure-function evaluation of ER {alpha} and ß interplay with SRC family coactivators. ER selective ligands. Biochemistry 40:6756–6765[CrossRef][Medline]
  40. Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, Suzawa M, Yanagisawa J, Kato S 1999 Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 19:1049–1055[Abstract/Free Full Text]
  41. Bramlett KS, Wu Y, Burris TP 2001 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol Endocrinol 15:909–922[Abstract/Free Full Text]
  42. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS 2000 Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-{alpha} and estrogen receptor-ß: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141:3534–3545[Abstract/Free Full Text]
  43. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J 2001 A unique PPAR{gamma} ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737–747[CrossRef][Medline]
  44. Ko L, Cardona GR, Iwasaki T, Bramlett KS, Burris TP, Chin WW 2002 Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. Mol Endocrinol 16:128–140[Abstract/Free Full Text]
  45. Smith CL, DeVera DG, Lamb DJ, Nawaz Z, Jiang YH, Beaudet AL, O’Malley BW 2002 Genetic ablation of the steroid receptor coactivator-ubiquitin ligase, E6-AP, results in tissue-selective steroid hormone resistance and defects in reproduction. Mol Cell Biol 22:525–535[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
EndocrinologyHome page
J. Chen, B.-S. An, L. Cheng, G. L. Hammond, and P. C. K. Leung
Gonadotropin-Releasing Hormone-Mediated Phosphorylation of Estrogen Receptor-{alpha} Contributes to fosB Expression in Mouse Gonadotrophs
Endocrinology, October 1, 2009; 150(10): 4583 - 4593.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. D. Rosen and M. L. Privalsky
Thyroid Hormone Receptor Mutations Found in Renal Clear Cell Carcinomas Alter Corepressor Release and Reveal Helix 12 as Key Determinant of Corepressor Specificity
Mol. Endocrinol., August 1, 2009; 23(8): 1183 - 1192.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kim, K. Heo, J. H. Kim, K. Kim, J. Choi, and W. An
Requirement of Histone Methyltransferase SMYD3 for Estrogen Receptor-mediated Transcription
J. Biol. Chem., July 24, 2009; 284(30): 19867 - 19877.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Yan, H. Erdem, R. Li, Y. Cai, G. Ayala, M. Ittmann, L.-y. Yu-Lee, S. Y. Tsai, and M.-J. Tsai
Steroid Receptor Coactivator-3/AIB1 Promotes Cell Migration and Invasiveness through Focal Adhesion Turnover and Matrix Metalloproteinase Expression
Cancer Res., July 1, 2008; 68(13): 5460 - 5468.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
G. F Ball and J. Balthazart
Individual variation and the endocrine regulation of behaviour and physiology in birds: a cellular/molecular perspective
Phil Trans R Soc B, May 12, 2008; 363(1497): 1699 - 1710.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. Li, Q. Kang, and D.-M. Wang
Constitutive Coactivator of Peroxisome Proliferator-Activated Receptor (PPAR{gamma}), a Novel Coactivator of PPAR{gamma} that Promotes Adipogenesis
Mol. Endocrinol., October 1, 2007; 21(10): 2320 - 2333.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Newton and N. S. Holden
Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor?
Mol. Pharmacol., October 1, 2007; 72(4): 799 - 809.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Higashimoto, P. Kuhn, D. Desai, X. Cheng, and W. Xu
Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1
PNAS, July 24, 2007; 104(30): 12318 - 12323.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. A. Moraes, K. E. Swales, J. A. Wray, A. Damazo, J. M. Gibbins, T. D. Warner, and D. Bishop-Bailey
Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets
Blood, May 1, 2007; 109(9): 3741 - 3744.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
B. Gershman, O. Puig, L. Hang, R. M. Peitzsch, M. Tatar, and R. S. Garofalo
High-resolution dynamics of the transcriptional response to nutrition in Drosophila: a key role for dFOXO
Physiol Genomics, March 14, 2007; 29(1): 24 - 34.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. J. Li, Z. Haque, Q. Lu, L. Li, R. Karas, and M. Mendelsohn
Steroid receptor coactivator 3 is a coactivator for myocardin, the regulator of smooth muscle transcription and differentiation
PNAS, March 6, 2007; 104(10): 4065 - 4070.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Cascio, V. Bartella, C. Garofalo, A. Russo, A. Giordano, and E. Surmacz
Insulin-like Growth Factor 1 Differentially Regulates Estrogen Receptor-dependent Transcription at Estrogen Response Element and AP-1 Sites in Breast Cancer Cells
J. Biol. Chem., February 9, 2007; 282(6): 3498 - 3506.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
A. Romano, B. Delvoux, D.-C. Fischer, and P. Groothuis
The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone
J. Mol. Endocrinol., February 1, 2007; 38(2): 331 - 350.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H.-G. Yoon and J. Wong
The Corepressors Silencing Mediator of Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Are Involved in Agonist- and Antagonist-Regulated Transcription by Androgen Receptor
Mol. Endocrinol., May 1, 2006; 20(5): 1048 - 1060.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K.-H. Song, T. Li, and J. Y. L. Chiang
A Prospero-related Homeodomain Protein Is a Novel Co-regulator of Hepatocyte Nuclear Factor 4{alpha} That Regulates the Cholesterol 7{alpha}-Hydroxylase Gene
J. Biol. Chem., April 14, 2006; 281(15): 10081 - 10088.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. P. Simmons, M. L. Peach, J. R. Friedman, M. M.B. Green, M. C. Nicklaus, and L. M. De Luca
Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action
Carcinogenesis, April 1, 2006; 27(4): 693 - 707.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
Y. Ogura, M. Azuma, Y. Tsuboi, Y. Kabe, Y. Yamaguchi, T. Wada, H. Watanabe, and H. Handa
TFII-I down-regulates a subset of estrogen-responsive genes through its interaction with an initiator element and estrogen receptor {alpha}
Genes Cells, April 1, 2006; 11(4): 373 - 381.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. A. Proia, B. W. Nannenga, L. A. Donehower, and N. L. Weigel
Dual Roles for the Phosphatase PPM1D in Regulating Progesterone Receptor Function
J. Biol. Chem., March 17, 2006; 281(11): 7089 - 7101.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
O. Y. Khan, G. Fu, A. Ismail, S. Srinivasan, X. Cao, Y. Tu, S. Lu, and Z. Nawaz
Multifunction Steroid Receptor Coactivator, E6-Associated Protein, Is Involved in Development of the Prostate Gland
Mol. Endocrinol., March 1, 2006; 20(3): 544 - 559.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Jiang, R. Meyer, K. Kang, C. K. Osborne, J. Wong, and S. Oesterreich
Scaffold Attachment Factor SAFB1 Suppresses Estrogen Receptor {alpha}-Mediated Transcription in Part via Interaction with Nuclear Receptor Corepressor
Mol. Endocrinol., February 1, 2006; 20(2): 311 - 320.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. R. Buchholz, B. D. Paul, and Y.-B. Shi
Gene-specific Changes in Promoter Occupancy by Thyroid Hormone Receptor during Frog Metamorphosis: IMPLICATIONS FOR DEVELOPMENTAL GENE REGULATION
J. Biol. Chem., December 16, 2005; 280(50): 41222 - 41228.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Safi, A. Kovacic, S. Gaillard, Y. Murata, E. R. Simpson, D. P. McDonnell, and C. D. Clyne
Coactivation of Liver Receptor Homologue-1 by Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1{alpha} on Aromatase Promoter II and Its Inhibition by Activated Retinoid X Receptor Suggest a Novel Target for Breast-Specific Antiestrogen Therapy
Cancer Res., December 15, 2005; 65(24): 11762 - 11770.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson
Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Endocr. Rev., December 1, 2005; 26(7): 898 - 915.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Z. Zhang, A. M. Olland, Y. Zhu, J. Cohen, T. Berrodin, S. Chippari, C. Appavu, S. Li, J. Wilhem, R. Chopra, et al.
Molecular and Pharmacological Properties of a Potent and Selective Novel Nonsteroidal Progesterone Receptor Agonist Tanaproget
J. Biol. Chem., August 5, 2005; 280(31): 28468 - 28475.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
K D S. A. Wansa and G. E O Muscat
TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors
J. Mol. Endocrinol., June 1, 2005; 34(3): 835 - 848.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
P. Chambon
The Nuclear Receptor Superfamily: A Personal Retrospect on the First Two Decades
Mol. Endocrinol., June 1, 2005; 19(6): 1418 - 1428.
[Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
T. Ishizuka and M. A. Lazar
The Nuclear Receptor Corepressor Deacetylase Activating Domain Is Essential for Repression by Thyroid Hormone Receptor
Mol. Endocrinol., June 1, 2005; 19(6): 1443 - 1451.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. J. M. Schaaf, L. J. Lewis-Tuffin, and J. A. Cidlowski
Ligand-Selective Targeting of the Glucocorticoid Receptor to Nuclear Subdomains Is Associated with Decreased Receptor Mobility
Mol. Endocrinol., June 1, 2005; 19(6): 1501 - 1515.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Bour, J.-L. Plassat, A. Bauer, S. Lalevee, and C. Rochette-Egly
Vinexin {beta} Interacts with the Non-phosphorylated AF-1 Domain of Retinoid Receptor {gamma} (RAR{gamma}) and Represses RAR{gamma}-mediated Transcription
J. Biol. Chem., April 29, 2005; 280(17): 17027 - 17037.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Yu, K. Markan, K. A. Temple, D. Deplewski, M. J. Brady, and R. N. Cohen
The Nuclear Receptor Corepressors NCoR and SMRT Decrease Peroxisome Proliferator-activated Receptor {gamma} Transcriptional Activity and Repress 3T3-L1 Adipogenesis
J. Biol. Chem., April 8, 2005; 280(14): 13600 - 13605.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Lee and M. L. Privalsky
Heterodimers of Retinoic Acid Receptors and Thyroid Hormone Receptors Display Unique Combinatorial Regulatory Properties
Mol. Endocrinol., April 1, 2005; 19(4): 863 - 878.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S.-E. Park, J. Xu, A. Frolova, L. Liao, B. W. O'Malley, and B. S. Katzenellenbogen
Genetic Deletion of the Repressor of Estrogen Receptor Activity (REA) Enhances the Response to Estrogen in Target Tissues In Vivo
Mol. Cell. Biol., March 1, 2005; 25(5): 1989 - 1999.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
S. H. Kim, A. Tamrazi, K. E. Carlson, and J. A. Katzenellenbogen
A Proteomic Microarray Approach for Exploring Ligand-initiated Nuclear Hormone Receptor Pharmacology, Receptor Selectivity, and Heterodimer Functionality
Mol. Cell. Proteomics, March 1, 2005; 4(3): 267 - 277.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
H.-P. Guan, T. Ishizuka, P. C. Chui, M. Lehrke, and M. A. Lazar
Corepressors selectively control the transcriptional activity of PPAR{gamma} in adipocytes
Genes & Dev., February 15, 2005; 19(4): 453 - 461.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
J. S Lewis, T J Thomas, R. G Pestell, C. Albanese, M. A Gallo, and T. Thomas
Differential effects of 16{alpha}-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells
J. Mol. Endocrinol., February 1, 2005; 34(1): 91 - 105.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Pogenberg, J.-F. Guichou, V. Vivat-Hannah, S. Kammerer, E. Perez, P. Germain, A. R. de Lera, H. Gronemeyer, C. A. Royer, and W. Bourguet
Characterization of the Interaction between Retinoic Acid Receptor/Retinoid X Receptor (RAR/RXR) Heterodimers and Transcriptional Coactivators through Structural and Fluorescence Anisotropy Studies
J. Biol. Chem., January 14, 2005; 280(2): 1625 - 1633.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. A. Jonas and M. L. Privalsky
SMRT and N-CoR Corepressors Are Regulated by Distinct Kinase Signaling Pathways
J. Biol. Chem., December 24, 2004; 279(52): 54676 - 54686.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
C M Klinge, S C Jernigan, K A Mattingly, K E Risinger, and J Zhang
Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors {alpha} and {beta} by coactivators and corepressors
J. Mol. Endocrinol., October 1, 2004; 33(2): 387 - 410.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
K. Steketee, A. C J Ziel-van der Made, H. A G M van der Korput, A. B Houtsmuller, and J. Trapman
A bioinformatics-based functional analysis shows that the specifically androgen-regulated gene SARG contains an active direct repeat androgen response element in the first intron
J. Mol. Endocrinol., October 1, 2004; 33(2): 477 - 491.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. S. Kim, J. Shigenaga, A. Moser, C. Grunfeld, and K. R. Feingold
Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response
Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E731 - E738.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Z. Chen, D. J. Eastburn, and M. Han
The Caenorhabditis elegans Nuclear Receptor Gene nhr-25 Regulates Epidermal Cell Development
Mol. Cell. Biol., September 1, 2004; 24(17): 7345 - 7358.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Cicatiello, R. Addeo, A. Sasso, L. Altucci, V. B. Petrizzi, R. Borgo, M. Cancemi, S. Caporali, S. Caristi, C. Scafoglio, et al.
Estrogens and Progesterone Promote Persistent CCND1 Gene Activation during G1 by Inducing Transcriptional Derepression via c-Jun/c-Fos/Estrogen Receptor (Progesterone Receptor) Complex Assembly to a Distal Regulatory Element and Recruitment of Cyclin D1 to Its Own Gene Promoter
Mol. Cell. Biol., August 15, 2004; 24(16): 7260 - 7274.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
T. Nakajima, S. Fujino, G. Nakanishi, Y.-S. Kim, and A. M. Jetten
TIP27: a novel repressor of the nuclear orphan receptor TAK1/TR4
Nucleic Acids Res., August 9, 2004; 32(14): 4194 - 4204.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
R. O'Lone, M. C. Frith, E. K. Karlsson, and U. Hansen
Genomic Targets of Nuclear Estrogen Receptors
Mol. Endocrinol., August 1, 2004; 18(8): 1859 - 1875.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
Y. A. Elhaji, J. Hui Wu, B. Gottlieb, L. K. Beitel, C. Alvarado, G. Batist, and M. A. Trifiro
An Examination of How Different Mutations at Arginine 855 of the Androgen Receptor Result in Different Androgen Insensitivity Phenotypes
Mol. Endocrinol., August 1, 2004; 18(8): 1876 - 1886.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
C. Elbi, D. A. Walker, M. Lewis, G. Romero, W. P. Sullivan, D. O. Toft, G. L. Hager, and D. B. DeFranco
A Novel In Situ Assay for the Identification and Characterization of Soluble Nuclear Mobility Factors
Sci. Signal., June 22, 2004; 2004(238): pl10 - pl10.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. A. Iannone, C. A. Simmons, S. H. Kadwell, D. L. Svoboda, D. E. Vanderwall, S.-J. Deng, T. G. Consler, J. Shearin, J. G. Gray, and K. H. Pearce
Correlation between in Vitro Peptide Binding Profiles and Cellular Activities for Estrogen Receptor-Modulating Compounds
Mol. Endocrinol., May 1, 2004; 18(5): 1064 - 1081.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Kajitani, T. Mizutani, K. Yamada, T. Yazawa, T. Sekiguchi, M. Yoshino, H. Kawata, and K. Miyamoto
Cloning and Characterization of Granulosa Cell High-Mobility Group (HMG)-Box Protein-1, a Novel HMG-Box Transcriptional Regulator Strongly Expressed in Rat Ovarian Granulosa Cells
Endocrinology, May 1, 2004; 145(5): 2307 - 2318.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
B. Herzog, R. K. Hall, X. L. Wang, M. Waltner-Law, and D. K. Granner
Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1{alpha}, as a Transcription Amplifier, Is Not Essential for Basal and Hormone-Induced Phosphoenolpyruvate Carboxykinase Gene Expression
Mol. Endocrinol., April 1, 2004; 18(4): 807 - 819.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Elbi, D. A. Walker, G. Romero, W. P. Sullivan, D. O. Toft, G. L. Hager, and D. B. DeFranco
Molecular chaperones function as steroid receptor nuclear mobility factors
PNAS, March 2, 2004; 101(9): 2876 - 2881.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Wang, C.-L. Hsu, J. Ni, P.-H. Wang, S. Yeh, P. Keng, and C. Chang
Human Checkpoint Protein hRad9 Functions as a Negative Coregulator To Repress Androgen Receptor Transactivation in Prostate Cancer Cells
Mol. Cell. Biol., March 1, 2004; 24(5): 2202 - 2213.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. Obradovic, M. Tirard, Zs. Nemethy, O. Hirsch, H. Gronemeyer, and O. F. X. Almeida
DAXX, FLASH, and FAF-1 Modulate Mineralocorticoid and Glucocorticoid Receptor-Mediated Transcription in Hippocampal Cells--Toward a Basis for the Opposite Actions Elicited by Two Nuclear Receptors?
Mol. Pharmacol., March 1, 2004; 65(3): 761 - 769.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. A. Lange
Making Sense of Cross-Talk between Steroid Hormone Receptors and Intracellular Signaling Pathways: Who Will Have the Last Word?
Mol. Endocrinol., February 1, 2004; 18(2): 269 - 278.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. H. Faulds, H. Olsen, L. A. Helguero, J.-A. Gustafsson, and L.-A. Haldosen
Estrogen Receptor Functional Activity Changes during Differentiation of Mammary Epithelial Cells
Mol. Endocrinol., February 1, 2004; 18(2): 412 - 421.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Sathya, C.-y. Chang, D. Kazmin, C. E. Cook, and D. P. McDonnell
Pharmacological Uncoupling of Androgen Receptor-mediated Prostate Cancer Cell Proliferation and Prostate-specific Antigen Secretion
Cancer Res., November 15, 2003; 63(22): 8029 - 8036.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
G. Zhou, Y. Hashimoto, I. Kwak, S. Y. Tsai, and M.-J. Tsai
Role of the Steroid Receptor Coactivator SRC-3 in Cell Growth
Mol. Cell. Biol., November 1, 2003; 23(21): 7742 - 7755.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K. De Bosscher, W. Vanden Berghe, and G. Haegeman
The Interplay between the Glucocorticoid Receptor and Nuclear Factor-{kappa}B or Activator Protein-1: Molecular Mechanisms for Gene Repression
Endocr. Rev., August 1, 2003; 24(4): 488 - 522.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. Albert, S. Gaudan, H. Knigge, A. Raetsch, A. Delgado, B. Huhse, H. Kirsch, M. Albers, D. Rebholz-Schuhmann, and M. Koegl
Computer-Assisted Generation of a Protein-Interaction Database for Nuclear Receptors
Mol. Endocrinol., August 1, 2003; 17(8): 1555 - 1567.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
J. M. Maglich, J. A. Caravella, M. H. Lambert, T. M. Willson, J. T. Moore, and L. Ramamurthy
The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily
Nucleic Acids Res., July 15, 2003; 31(14): 4051 - 4058.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Frasor, D. H. Barnett, J. M. Danes, R. Hess, A. F. Parlow, and B. S. Katzenellenbogen
Response-Specific and Ligand Dose-Dependent Modulation of Estrogen Receptor (ER) {alpha} Activity by ER{beta} in the Uterus
Endocrinology, July 1, 2003; 144(7): 3159 - 3166.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. M. Peehl, A. V. Krishnan, and D. Feldman
Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer
J. Nutr., July 1, 2003; 133(7): 2461S - 2469.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. L. M. Sutton and P. N. MacDonald
Vitamin D: More Than a "Bone-a-Fide" Hormone
Mol. Endocrinol., May 1, 2003; 17(5): 777 - 791.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Liu, K. S. Knappenberger, H. Kack, G. Andersson, E. Nilsson, C. Dartsch, and C. W. Scott
A Homogeneous in Vitro Functional Assay for Estrogen Receptors: Coactivator Recruitment
Mol. Endocrinol., March 1, 2003; 17(3): 346 - 355.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McKenna, N. J.
Right arrow Articles by O’Malley, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McKenna, N. J.
Right arrow Articles by O’Malley, B. W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals